

# CLEC2D Polyclonal Antibody

Purified Rabbit Polyclonal Antibody (Pab)

Catalog # AP58048

## Product Information

<b>Application</b>	IHC-P, IHC-F, IF, E
<b>Primary Accession</b>	<a href="#">Q9UHP7</a>
<b>Reactivity</b>	Rat, Pig, Dog
<b>Host</b>	Rabbit
<b>Clonality</b>	Polyclonal
<b>Calculated MW</b>	21849
<b>Physical State</b>	Liquid
<b>Immunogen</b>	KLH conjugated synthetic peptide derived from human CLEC2D
<b>Epitope Specificity</b>	101-207/207
<b>Isotype</b>	IgG
<b>Purity</b>	affinity purified by Protein A
<b>Buffer</b>	0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
<b>SUBCELLULAR LOCATION</b>	Cell membrane; Single-pass type II membrane protein. Cell surface. Isoform 2, 4: Endoplasmic reticulum.
<b>SIMILARITY</b>	Contains 1 C-type lectin domain.
<b>SUBUNIT</b>	Homodimer or heterodimer; disulfide-linked.
<b>Important Note</b>	This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
<b>Background Descriptions</b>	This gene encodes a member of the natural killer cell receptor C-type lectin family. The encoded protein inhibits osteoclast formation and contains a transmembrane domain near the N-terminus as well as the C-type lectin-like extracellular domain. Several alternatively spliced transcript variants have been identified, but the full-length nature of every transcript has not been defined.

## Additional Information


<b>Gene ID</b>	29121
<b>Other Names</b>	C-type lectin domain family 2 member D, Lectin-like NK cell receptor, Lectin-like transcript 1, LLT-1, Osteoclast inhibitory lectin, CLEC2D, CLAX, LLT1, OCIL
<b>Target/Specificity</b>	Detected in fetal heart, brain, lung, chondrocytes, perichondrium and osteoblasts, and in adult splenocytes, thymocytes, lymph-node cells, osteoblasts, growth plate chondrocytes and skeletal muscle overlying the bone (at protein level). Ubiquitous. Detected in thymus, bone marrow, lung, gut, heart, skeletal muscle, ovary, spleen, ileum, liver and kidney.
<b>Dilution</b>	IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500,Flow-Cyt=1 µg /test,ELISA=1:5000-10000

Format	0.01M TBS(pH7.4) with 1% BSA, 0.09% (W/V) sodium azide and 50% Glyce
Storage	Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.

Protein Information

Name	CLEC2D
Synonyms	CLAX, LLT1, OCIL
Function	Receptor for KLRB1 that protects target cells against natural killer cell-mediated lysis (PubMed: <a href="#">16339513</a> , PubMed: <a href="#">20843815</a> ). Inhibits osteoclast formation (PubMed: <a href="#">14753741</a> , PubMed: <a href="#">15123656</a> ). Inhibits bone resorption (PubMed: <a href="#">14753741</a> ). Modulates the release of interferon-gamma (PubMed: <a href="#">15104121</a> ). Binds high molecular weight sulfated glycosaminoglycans (PubMed: <a href="#">15123656</a> ).
Cellular Location	Cell membrane; Single-pass type II membrane protein [Isoform 4]: Endoplasmic reticulum
Tissue Location	Detected in peripheral blood leukocytes, osteoblasts, lymph node, thymus and spleen. Isoform 1, isoform 2 and isoform 4 are expressed in T- and B-lymphocytes, and at lower levels in NK cells. They are also expressed in B-cell lines and LPS-matured monocyte-derived dendritic cells.

Images



Positive control: (mo)Splenocytes(2% Paraformaldehyde-fixed )  
Isotype Control Antibody: Rabbit IgG; Dilution: 1 µg in 100 µl 1 X PBS containing 0.5% BSA  
Secondary Antibody: Goat anti-rabbit IgG-FITC; Dilution: 1:200 in 1 X PBS containing 0.5% BSA  
Primary Antibody catalog number: AP58048; Dilution: 1 µg in 100 µl 1X PBS containing 0.5% BSA

Blank control: mouse thymouses(blue)  
Isotype Control Antibody: Rabbit IgG(orange) ;  
Secondary Antibody: Goat anti-rabbit IgG-FITC(white blue), Dilution: 1:100 in 1 X PBS containing 0.5% BSA ;  
Primary Antibody Dilution: 1 µl in 100 µl1X PBS containing 0.5% BSA(green).

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.